Cargando…
Effect of cognitive–behavioural therapy on resilience and relapse in adult patients with substance use disorder: a systematic review protocol
INTRODUCTION: Approximately 0.5 million fatalities per year are attributed to substance use disorder (SUD). SUD is refractory to therapy and has a high relapse rate. Cognitive deficits are also common in patients with SUD. Cognitive–behavioural therapy (CBT) is a promising treatment that may build r...
Autores principales: | Mhaidat, Ibraheem, Taherian, Mohammad Reza, Hashemi Nazari, Seyed Saeed, Mosavi-Jarrahi, Alireza, Yeganeh, Haniye, Al-Yateem, Nabeel, Al Marzouqi, Amina M, Rahman, Syed Azizur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186399/ https://www.ncbi.nlm.nih.gov/pubmed/37173114 http://dx.doi.org/10.1136/bmjopen-2022-067115 |
Ejemplares similares
-
Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study
por: Maatouk, Imad, et al.
Publicado: (2018) -
Health care utilisation preceding relapse or second malignant neoplasm after childhood acute lymphoblastic leukaemia: a population-based matched cohort study
por: Jensen, Karen Schow, et al.
Publicado: (2021) -
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma
por: Kendall, Jessica, et al.
Publicado: (2022) -
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
por: Tang, Xiao-Yi, et al.
Publicado: (2016) -
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
por: George, Philip, et al.
Publicado: (2020)